J&J opts out of Horizon leaving out Amgen, Sanofi as only bidders

Johnson & Johnson (NYSE:JNJ) confirmed on Saturday that the company would not intend to bid for Horizon Therapeutics (HZNP), leaving out rivals Amgen (AMGN) and Sanofi (SNY) (OTCPK:SNYNF) as potential contenders to acquire the Ireland-based biotech. Horizon (HZNP) shares surged in the post-market trading Tuesday after the company disclosed early...
Picture for J&J opts out of Horizon leaving out Amgen, Sanofi as only bidders
Motley Fool

Is Biogen Stock a Buy Now?

Biogen could commercialize its latest potential Alzheimer's therapy sometime next year. If lecanemab meets expectations, shareholders could see the benefits for years to come. But last year's debacle with Aduhelm makes it harder to believe that lecanemab will succeed. You’re reading a free article with opinions that may differ from...
Picture for Is Biogen Stock a Buy Now?
West Jordan Journal

Westland Elementary celebrates 50 years

The 50th Homecoming celebration of Westland Elementary was a success, said Crystal Whitehead, who organized the event. “We had a great turnout,” she said. “I think it was beyond a lot of people's expectations. We had a lot of past and current teachers, alumni and a lot of the community.”
Motley Fool

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio's medicine to delay type 1 diabetes recently earned FDA approval. This new therapy shows solid commercial potential in the market. That said, serious risks remain associated with investing in Provention Bio. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services....

VSU announces the Center for Biotechnology, Genomics, & Bioinformatics

VSU announces the Center for Biotechnology, Genomics, & Bioinformatics. VIRGINIA STATE UNIVERSITY, VA—Virginia State University (VSU) is excited to announce the establishment of the VSU Center for Biotechnology, Genomics, and Bioinformatics (VSU CeBiGeBi). The VSU CeBiGeBi, believed to be unique among HBCUs nationwide, will be a hub for interdisciplinary education and research on the VSU campus.

Biotech firm Amgen says experimental obesity drug has promising durability

LOS ANGELES – US biopharmaceutical firm Amgen’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday. The small Phase I trial found that patients maintained...

Shares making the largest strikes noon: Zscaler, Marvell Expertise, DoorDash and extra

Take a look at the businesses making headlines in noon buying and selling. – The cloud safety firm’s shares dipped 10.7% following its quarterly earnings report, regardless of Zscaler posting robust outcomes. Earnings and income have been stronger than analysts’ expectations. The corporate additionally forecast better-than-expected earnings and income for its fiscal second quarter and full 12 months.

3 Stocks to Buy Hand Over Fist in December

High conviction. That’s what you want to have with the stocks you buy. Such stocks are ones that you can be enthusiastic about — and buy heavily. We asked three Motley Fool contributors to identify stocks for which they have high convictions about buying right now. Here’s why they think that AbbVie (NYSE: ABBV), Exelixis (NASDAQ: EXEL), and Vertex Pharmaceuticals (NASDAQ: VRTX) are stocks to buy hand over fist in December.

Health: the new Alzheimer’s drug, what is it and when is it available?

As trial outcomes deliver hope of an efficient therapy, Lisa Salmon asks The Alzheimer’s Society what it means for individuals proper now. In the end, it appears a drug has been discovered to deal with Alzheimer’s illness. Lecanemab has been proven in trials to gradual the progress of...

Swedish scientist behind Alzheimer’s drug has big ambitions

As Japanese drugmaker Eisai this week presented data confirming it had developed the first drug to slow cognitive decline in Alzheimer’s patients, the audience at a conference in San Francisco burst into applause. Among those in attendance was Lars Lannfelt, a little-known Swedish scientist who invented the groundbreaking drug,...

1250 Crore Investment in the Biotechnology Sector, garnered through Make in Odisha Conclave 2022

The Science and Technology department and the Association of Biotechnology Led Enterprise (ABLE) signed a memorandum of understanding (MOU) at the MIO conclave 2022 with the intention of bringing biotech industries to Odisha to mentor and nurture biotech startups, bringing international knowledge groups to Odisha for investment purposes, and preparing a conducive biotech policy for Odisha.

MIO Conclave 2022 boosts Odisha’s bio-economy

Bhubaneswar: During the MIO 2022 conclave, the science and technology department signed a memorandum of understanding with the Association of Biotechnology Led Enterprise (ABLE) to bring biotech industries to Odisha to mentor and nurture biotech startups, bring groups of international knowledge in Odisha for investment purposes and to prepare an enabling environment for Biotechnology Policy for Odisha.

£10,000 available: how much should I invest in growth stocks?

Investing in growth stocks tends to be higher risk than value stocks. There are some pretty simple reasons for this. But let’s assume I have £10,000 to invest. The question is, how much of my money should I be investing in growth stocks?. Why are growth stocks riskier?

The twentysomethings changing the future of agriculture

Electric-powered trailers, modular vertical farming units, mushroom-picking robots, probiotics for plants and more-efficient fertilisers. These are just some of the inventions created by the talented men and women under 30-years of age who have made this year’s Forbes magazine’s 30 Under 30 list. The 2023 edition of the...

Europe To Have Expanded Entry To Psychedelic-Assisted

Europe To Have Expanded Entry To Psychedelic-Assisted, ,. Psychedelics biotech Awakn Life Sciences Corp. AWKNF introduced the continuation of its Nordic growth plans with a brand new 5-year lease for the opening of a clinic within the middle of Trondheim. Awakn’s CEO Anthony Tennyson acknowledged this can be a “actual...